Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. - Wikidata - awgldk - TriplyDB

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.

http://www.wikidata.org/entity/Q42441080

about

Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab Epithelial membrane protein-1 is a biomarker of gefitinib resistance.Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies Will kinase inhibitors make it as glioblastoma drugs?In vitro and in vivo models for analysis of resistance to anticancer molecular therapies The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered Molecular pathology of lung cancer: key to personalized medicine.Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors Cellular effects of HER3-specific affibody molecules Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.EGFR associated expression profiles vary with breast tumor subtype Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma.Analysis of the molecular networks in androgen dependent and independent prostate cancer revealed fragile and robust subsystems.Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation Multiple roles and therapeutic implications of Akt signaling in cancer.Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts.Understanding resistance to EGFR inhibitors-impact on future treatment strategies Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling.Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer Targeting the function of the HER2 oncogene in human cancer therapeutics.Metformin and erlotinib synergize to inhibit basal breast cancer.MicroRNA gene dosage alterations and drug response in lung cancer Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.Clinical development of phosphatidylinositol-3 kinase pathway inhibitors

P2860

Q24313194-3F837C41-FF16-4690-9E74-2E82D638DF80 Q24535592-878DB912-4680-47E9-BDCF-C8FF46F42602 Q24633878-E5201CE3-6CC0-4096-BAE0-1CC0B6FF376A Q24810622-C4A85A2D-B390-4C81-B874-DDC92226C040 Q26822717-71CFCA79-6300-4499-A896-F19F86D91406 Q26852366-D670CB44-62E6-47CF-981A-E5581A3B9958 Q27012684-4F81F2FC-AA52-4F98-87AA-D863A89D9A46 Q27014174-EC43822E-5DA2-42AB-BF00-93BB0A1488C3 Q27015045-A74F26EF-97C0-4C17-ACE8-385FA14C8B1C Q27691299-3532BB4E-CF7C-4471-9978-6B810C41F849 Q27851396-EA884120-5F95-4213-A1C9-B7F5A335EBF0 Q27852452-AD9DA95E-3EEA-40DC-B648-4BB8B21FAB55 Q28472048-85973BC3-F34D-4F32-AF79-5C9F2554C65B Q28478344-ADF41FA8-FD97-4210-9CF5-5A389EBEC80D Q28727774-BAC5478C-BDE4-44CB-93E2-8DCA294AE3BF Q30438487-F6E5D959-E9EC-4527-B3CB-27D0712E48B7 Q33292502-61818322-C6D4-4F20-94C4-C80E98D01C74 Q33397545-08A1D576-5302-4CBA-B8F8-E2A7F7E4B65F Q33529070-F40C4CEE-34EC-489A-9F2D-7130281A0107 Q33608491-7E6A3980-D4BE-44B5-BD70-93DBC6CEC0CB Q33691211-2FB19DFF-BA56-4069-A895-2C6F63C1A6F1 Q33733313-123C384E-8174-44D1-AB22-E6CF3B952A9A Q33778905-184D67D3-4FA5-49A8-9469-21F5E4C48FD4 Q33915992-B45138D4-7A0D-4940-960D-6DB4C2F90BCD Q33924908-F5D602FE-ADCD-4DBF-BAE0-4DD86F3E7AF8 Q33928631-32BC8C2D-49D9-4421-B7DD-4F08811A3ACF Q34067863-94B20F51-410E-433D-968F-1D47DBE1E081 Q34088424-041C561C-810F-47B6-B51B-FD314F828BD9 Q34093266-4225C7C2-257A-4D8F-968D-D07B1132B666 Q34132872-5913A4EB-1BA6-4A4C-A7C7-93BFD6F5C1FF Q34485373-72D3C4D4-CA4C-4E84-93F3-36D88B9C2888 Q34524510-40379271-BAD8-4B34-8614-A92AC012E705 Q34557318-53463160-D3FF-4194-AEA5-B6AE84AB9F2C Q34686900-BEAFCA3D-3C0F-45DF-8E64-E490BFE79437 Q34766486-F5503FC9-C16D-4BCF-AC00-69D20D04B06C Q34786488-CEE06416-D1C6-4FCC-9D89-90168A242DE4 Q34897598-84FF9A97-D17B-4168-ADCA-53E1BCA0ADA5 Q35012485-B3D64C04-BA7E-4055-A94F-9FFE830CA28E Q35469548-8ABD0B40-8172-4F33-BC2D-67B8FF2EA1BF Q35566234-0DD333DF-A3DB-4A6A-874C-913C9606C6F0

P2860

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.

http://www.wikidata.org/entity/Q42441080

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Loss of PTEN/MMAC1/TEP in EGF ...... FR tyrosine kinase inhibitors.

@en

Loss of PTEN/MMAC1/TEP in EGF ...... FR tyrosine kinase inhibitors.

@nl

type

label

Loss of PTEN/MMAC1/TEP in EGF ...... FR tyrosine kinase inhibitors.

@en

Loss of PTEN/MMAC1/TEP in EGF ...... FR tyrosine kinase inhibitors.

@nl

prefLabel

Loss of PTEN/MMAC1/TEP in EGF ...... FR tyrosine kinase inhibitors.

@en

Loss of PTEN/MMAC1/TEP in EGF ...... FR tyrosine kinase inhibitors.

@nl

P1433

Q42441080-C77BA3AE-CE93-4EA2-AC8D-51C788E51A6E

P1476

Q42441080-3B57E3C0-D61F-4C8B-A7D9-42F8295E5F53

P2093

Q42441080-44A9C61A-BD09-445D-B1B8-19531E40FE7F

Q42441080-53FCC2E1-7188-4870-B0E5-EE2F34146D66

Q42441080-5794069E-FDDF-4523-AC6F-23D03233C0D0

Q42441080-6E2029AC-AE30-4F59-B17C-AC376AEE22D7

Q42441080-91A78AFF-0EE4-4235-AAA4-DC7575BA9990

Q42441080-CB820AA7-084A-499E-BCC9-5C7F7D219BD6

Q42441080-E5DB19D4-3DEC-44B9-8B4A-EEE6AF3DC7E4

Q42441080-E6D05260-5CC2-4F73-ADCC-F10948E16D8E

Q42441080-F5C95DC6-C1EF-4537-A130-5AF5092C1F07

Q42441080-F86FF16B-7C77-4DC6-BF31-F44CA311178E

P2860

Q42441080-002308C7-02D3-4766-A380-D5EFA6F85857

Q42441080-00C3E2AE-D5D9-494A-A236-2D48A2A5CD9C

Q42441080-0B0814BE-2A5B-4F4D-BFFC-A7DE39E40C72

Q42441080-0DD3BF4F-F3CE-4CB7-A384-94C31CAAB108

Q42441080-19BEA8DB-9CBC-4C43-9832-E4CD72CFC0B1

Q42441080-1D372F5A-1AF9-41F9-807F-B076BE13EE15

Q42441080-1D6A5228-B944-48FE-A10E-4EE43391AF5D

Q42441080-1E4F0CA2-39AA-44A9-B19E-8D22B82824AD

Q42441080-30353655-A239-4E77-9096-502B5F0AEA4E

Q42441080-35C35906-87E0-4952-B59F-3855F5CDDD8F

P2888

Q42441080-85768ECF-C696-46A1-9D60-1C697A23B629

P304

Q42441080-CD55AFA4-BF53-434D-AC24-2DFEB60D0252

P31

Q42441080-F91CA858-1E1D-4264-BF3F-094AC92879C3

P356

Q42441080-86D39311-DD97-4A64-9FBF-33093D776007

P407

Q42441080-DFE897E7-0853-4488-9EBD-F5433F1F6524

P433

Q42441080-F19EA14E-10AD-463D-99D5-98CF71C0AB94

P478

Q42441080-0E7EDACB-C734-447D-A5F7-932365ACD9E7

P577

Q42441080-93A70707-5145-465B-A1AF-A03859051DB9

P5875

Q42441080-8C659978-CD2D-4C5D-B623-75089866F4B8

P6179

Q42441080-9DB45A75-37E8-4445-A183-D760BAF4DEB8

P698

Q42441080-9D6BEB77-95AC-498C-BCE7-AF6B75793EB9

P356

P1433

P1476

Loss of PTEN/MMAC1/TEP in EGF ...... FR tyrosine kinase inhibitors.

@en

P2093

Andrea Basso

http://www.w3.org/2001/XMLSchema#string

Carlos L Arteaga

http://www.w3.org/2001/XMLSchema#string

Christoph A Ritter

http://www.w3.org/2001/XMLSchema#string

F Michael Yakes

http://www.w3.org/2001/XMLSchema#string

Gordon B Mills

http://www.w3.org/2001/XMLSchema#string

Incheol Shin

http://www.w3.org/2001/XMLSchema#string

Junji Tsurutani

http://www.w3.org/2001/XMLSchema#string

Neal Rosen

http://www.w3.org/2001/XMLSchema#string

Phillip A Dennis

http://www.w3.org/2001/XMLSchema#string

Roberto Bianco

http://www.w3.org/2001/XMLSchema#string

P2860

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play?

Untangling the ErbB signalling network

AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation

PTEN: life as a tumor suppressor

Mutation analysis of the PTEN/MMAC1 gene in lung cancer

PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway

A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling

Cellular survival: a play in three Akts

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

P2888

P304

2812-2822

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.ONC.1206388

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2003-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7296902

http://www.w3.org/2001/XMLSchema#string

P6179

1004564925

http://www.w3.org/2001/XMLSchema#string

P698

12743604

http://www.w3.org/2001/XMLSchema#string